When Americans complains about “drug prices,” most are actually complaining about the share of costs they pay—and how those costs are computed. Addressing patient affordability issues therefore requires a deep understanding of the U.S. drug channel.
Today, I review four crucial issues that the new Congress could tackle to address affordability, patients' out-of-pocket obligations, and prescription prices. I also highlight some of the existing and proposed legislative efforts.
Our complex channel cannot be fixed with simplistic solutions. It may seem unlikely that we will get bipartisan legislation that sensibly addresses the distortions and challenges in our drug pricing system. But I can dream, can’t I?
Speaking of next year, Drug Channels Institute will host an exclusive live webinar, Drug Channels Outlook 2021, on December 18, 2020, from 12:00 p.m. to 1:15 p.m. ET. Click here to learn more and sign up.
Source: Post feed
